Abstract: The present invention relates to inorganic salts of nicotinic acid mononucleotides and compositions of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+: wherein A, M1, M2, k, R1, R2, and R3 are as described herein.

Abstract: Among the various aspects of the present disclosure is the provision of compositions of NRF2 inhibiting agents and methods of use thereof. These agents can be useful for cancer treatment, including as radiosensitizing agents and as chemotherapeutic sensitizing agents.

Abstract: The present invention relates to amino acid salts of nicotinic acid mononucleotides and nicotinamide mononucleotides and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+: wherein A, M1, M2, R1, R2, and R3 are as described herein.

Abstract: The present invention relates to amino acid salts of nicotinic acid and nicotinamide and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+: wherein A, L, M1, M2, R1, R2, and R3 are as described herein.

Abstract: The present invention relates to inorganic salts of nicotinamide mononucleotides and compositions of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+: wherein A, M, k, R1 and R2 are as described herein.

Abstract: The present invention relates to amino acid salts of nicotinic acid ribosides and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+: wherein M1, R1, R2, and R3 are as described herein.

Abstract: The present invention relates to inorganic salts of nicotinic acid mononucleotides and compositions of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+: wherein A, M1, M2, k, R1, R2, and R3 are as described herein.

Abstract: Among the various aspects of the present disclosure is the provision of composition comprising itaconate, malonate, n or a derivative thereof and uses thereof. The present disclosure provides for methods of treating Ikb-? associated disease, disorder, or conditions comprising administering a therapeutically effective amount of an itaconate, malonate, or a derivative thereof to a subject. In some embodiments, the therapeutically effective amount reduces or prevents tumor growth, inflammation, or an immune response. Another aspect of the present disclosure includes a method to suppress Ikb-? induction comprising administering an itaconate, malonate, or a derivative thereof.

Abstract: The present disclosure relates to compositions and methods of modulating B lymphocyte activity, and organ protection after acute injury. In particular, PEG-Pirfenidone has increased half-life, improved bioavailability and is equipotent in modulating B cell activity and is particularly useful as protective agents from acute organ damage and disease caused by dysregulation of B cell activity.

Abstract: The present invention relates to inorganic salts of nicotinic acid mononucleotides and compositions of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+: wherein A, M1, M2, k, R1, R2, and R3 are as described herein.

Abstract: The present invention relates to inorganic salts of nicotinic acid mononucleotides and compositions of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+: wherein A, M1, M2, k, R1, R2, and R3 are as described herein.

Abstract: A tensioning device for a traction drive comprises: a base body, a tensioning arm pivotably mounted about a pivot axis relative to the base body by a radial bearing, wherein one of the base body and tensioning arm has an annular carrier portion axially supported relative to the other of the tensioning arm and base body by a first axial bearing in a first direction and by a second axial bearing in a second direction, a first sealing element connected to said support portion for sealing said first axial bearing, a second sealing element connected to said support portion for sealing said second axial bearing, wherein the first and second axial bearings are made of a different material than the first and second sealing elements, spring means via which the tensioning arm is supported in the circumferential direction against the base body, and a tensioning roller which is rotatably mounted on the tensioning arm and serves to tension a traction means, wherein the first sealing element and the second sealing element

Abstract: Methods for enhancing cognitive function are disclosed.

Abstract: Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the ? opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other ? opioid receptor-mediated conditions.

Abstract: Novel sulfamoyl benzamide compounds, pharmaceutical compositions containing the sulfamoyl benzamide compounds, and methods of their pharmaceutical use are disclosed. In certain embodiments, the sulfamoyl benzamide compounds are agonists and/or ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, inflammation, auto-immune diseases, ischemic conditions, immune-related disorders, hypertension, neurological disorders, and neurodegenerative diseases, for providing cardioprotection against ischemic and reperfusion effects, for inducing apoptosis in malignant cells, for inhibiting mechanical hyperalgesia associated with nerve injury, and as an appetite stimulant.

Abstract: Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the ?-opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other ?-opioid receptor-mediated diseases, disorders, and/or conditions.

Abstract: Certain quinolizidine and octahydropyridopyrazine compounds, pharmaceutical compositions, and methods of their use, inter alia, as opioid receptor antagonists are disclosed.

Abstract: Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the ? opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other ? opioid receptor-mediated conditions.

Abstract: Certain 4-aryl-piperidine compounds, including N-substituted 9?-substituted-5-(3-substituted-phenyl)morphans and N-substituted octahydro-4a-(3-hydroxyphenyl)-10a-methyl-benzo[g]isoquinolines, pharmaceutical compositions, and methods of their use, inter alia, as opioid antagonists are disclosed.

Abstract: Novel 3,4-disubstituted-4-aryl-piperidine compounds are disclosed. Pharmaceutical compositions containing the 3,4-disubstituted-4-aryl-piperidine compounds and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as antagonists of opioid receptors.